Changes to the Executive Management

Core Viewpoint - BioPorto A/S announced the resignation of CFO Niels Høy Nielsen, who will continue in his role until March 2026, as he transitions to a new position at another company [1][2]. Company Overview - BioPorto is an in vitro diagnostics company focused on improving patient management through actionable biomarkers, particularly in areas with significant unmet medical needs [4]. - The company utilizes its expertise in antibodies and assay development to create innovative products aimed at enhancing clinical and economic outcomes for patients and healthcare providers [4]. Key Products - BioPorto's flagship products are based on the NGAL biomarker, which aids in the risk assessment and diagnosis of Acute Kidney Injury (AKI) [5]. - The NGAL tests allow for quicker identification of patients at risk of AKI compared to standard care measurements, facilitating earlier intervention and tailored management strategies [5]. Company Operations - BioPorto operates facilities in Copenhagen, Denmark, and Boston, MA, USA, and is listed on the Nasdaq Copenhagen stock exchange [6].